查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995395

乳房切片市场：2026-2032年全球市场预测（依产品类型、手术类型、导引方法、切片检查部位、最终用户及临床适应症划分）

Breast Biopsy Market by Product Type, Procedure Type, Guidance Modality, Biopsy Site, End User, Clinical Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年乳房切片市场价值 19 亿美元，预计到 2025 年将成长至 20.2 亿美元，复合年增长率为 6.63%，到 2032 年将达到 31.7 亿美元。

主要市场统计数据
基准年 2024 19亿美元
预计年份：2025年 20.2亿美元
预测年份：2032年 31.7亿美元
复合年增长率 (%) 6.63%

我们将建立一个以患者为中心的乳房切片护理综合框架，将临床结果、医疗设备创新和医疗机构策略连结起来。

乳房疾病的诊断过程依赖于及时、准确且微创的组织取样。成像技术和医疗设备工程的进步为临床医生提供了更多样化的切片检查选择，但随着患者对安全性和舒适度的期望不断提高，手术流程的优先顺序也在改变。因此，医疗机构的决策者、製造商和临床团队必须权衡日益增长的准确性需求与不同医疗环境的营运限制。

成像技术的进步、医疗设备的模组化以及以病人为中心的服务模式，是如何重塑乳房切片护理的临床工作流程和采购重点的？

乳房切片领域正经历着一场变革，其驱动力包括技术小型化、成像技术的整合以及对以患者为中心的工作流程的重新重视。高解析度超音波和先进的磁振造影序列等影像方法变得更加普及和互通性，使临床医生能够更准确地识别病灶并缩短手术时间。同时，医疗设备製造商正致力于模组化设计，优先考虑人体工学、即时回馈以及与多种影像平台的兼容性。

评估 2025 年价格调整对下游营运和供应链的影响，并检视相关人员的采购策略。

改变医疗设备采购和临床报销经济计算方式的政策可能会对整个供应链和医疗服务系统产生连锁反应。 2025年实施的关税调整带来了明显的成本压力，影响了采购决策、定价策略和库存管理的地理布局。为此，采购团队重新评估了供应商多样性，优化了物流，并实施了合约保障措施，以降低跨境关税波动带来的风险。

透过对医疗设备技术、手术类型和最终用户环境进行详细的細項分析，可以製定有针对性的商业化和临床引入策略。

细分市场洞察揭示了不同技术、手术类型和终端使用者环境之间存在的细微需求差异，因此需要差异化的商业性和临床策略。在技​​术领域，核心针穿刺活检设备占据了手术选择的大部分，提供全自动和半自动配置，兼顾了处理能力和操作者控制。细针穿刺切片穿刺针包括具有增强超音波影像清晰度的迴声增强型，以及在细胞学主导流程中仍发挥重要作用的标准针。真空辅助系统包含两类产品：一类是专为临床环境便利性而最佳化的手持式设备，另一类是专为复杂病变和高容量环境而设计的桌上型平台。

影响北美、欧洲、中东和非洲以及亚太地区产品引进、分销和临床支援优先事项的区域趋势和策略考量。

区域趋势影响临床实践模式和商业性需求，而从地理角度出发的细緻观点有助于相关人员优先考虑市场准入、分销和支援方面的投资。在美洲，医疗保健系统强调以价值为导向的医疗服务、提高手术效率和扩大门诊服务，这推动了对使用者友善设备和整合工作流程解决方案的需求。该地区的报销机制和医院采购流程往往优先考虑可证实的临床效益和完善的售后支援。

竞争格局和企业级策略讯号凸显了透过整合解决方案、临床伙伴关係和卓越服务实现差异化的重要性。

乳房切片生态系统的竞争动态以技术差异化、服务主导的价值提案和策略联盟为特征。领先的医疗设备开发商正日益将数位化工具和硬体产品结合，以改善手术规划、文件记录和术后追踪。因此，能够提供涵盖设备可靠性、影像互通性和资料整合等端到端解决方案的公司，在与医疗机构建立长期合作关係方面具有优势。

为製造商和医疗保健机构提供实用策略指南，以协调创新、赋能和价值链韧性，从而加速采用和价值实现。

行业领导企业应采取平衡的策略，将产品创新与营运支援和临床医生能力提升相结合，以加速产品普及并保持价值。首先，优先考虑降低设定复杂性、同时提升操作流程人体工学和影像相容性的设备设计。这种方法可以缩短掌握时间并提高处理能力。其次，投资于临床医生教育计画和基于模拟的培训，以加强技术一致性并支持品质指标。第三，拓展服务范围，使其超越硬体本身，涵盖流程咨询、远端故障排除和结果追踪工具，进而加强客户关係。

透过文献整合、临床医生访谈和资料三角验证，我们采用稳健且多方面的调查方法来检验策略见解并减轻分析限制。

本研究采用结构化且透明的调查方法，整合了相关证据，旨在确保分析的严谨性和实际应用价值。研究首先对同侪审查的临床文献、监管申报文件和医疗设备技术文件进行全面审查，以建立对安全性概况、手术适应症和器械特性的基础性理解。随后，透过对介入放射科医生、乳房外科医生、采购经理和器械工程师的访谈，进行了一项定性初步调查，以确定实际应用中的驱动因素、障碍和尚未解决的需求。

整合策略挑战，展示临床证据、商业化敏捷性和营运韧性如何决定乳房切片护理的长期成功。

一项整合临床趋势、技术进步和营运实际情况的分析凸显了短期挑战，其中准确性、患者体验和供应链韧性是决定成败的关键因素。如果医疗设备在目标准确性、人体工学和与影像系统的互通性方面有显着改进，并且配备完善的培训和服务基础设施，则很可能被临床应用所接受。同时，医疗系统将继续优先考虑检测能力和成本控制，从而催生对可在门诊和住院环境中实施的模组化解决方案的需求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：乳房切片市场：依产品类型划分

  • 切片穿刺针
  • 导航系统
  • 癌症切片检查
  • 耗材和配件

第九章：乳房切片市场：依手术类型划分

  • 核心针穿刺切片
  • 穿刺切片检查
  • 细针穿刺切片检查
  • 手术/开放式切片检查
    • 切除切片检查
    • 切片检查

第十章：乳房切片市场：依引导法划分

  • 超音波引导下切片检查
  • 立体定位X射线引导切片检查
  • 磁振造影引导切片检查

第十一章乳房切片市场：依切片检查部位划分

  • 乳腺实质
  • 腋窝和区域淋巴结
  • 乳头导管结构

第十二章：乳房切片市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十三章：乳房切片市场：依临床适应症划分

  • 早期癌症筛检
  • 治疗方法方案
  • 监测復发情形及治疗进展

第十四章乳房切片市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：乳房切片市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章乳房切片市场：按国家/地区划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国乳房切片市场

第十八章：中国乳房切片市场

第十九章 竞争情势

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • Argon Medical Devices, Inc.
  • Becton Dickinson and Company
  • Cook Group Incorporated
  • Danaher Corporation
  • Exact Sciences Corporation
  • FUJIFILM Corporation
  • GE HealthCare
  • Hologic, Inc.
  • Medtronic PLC
  • Merit Medical Systems, Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
Product Code: MRR-4F4C36263235

The Breast Biopsy Market was valued at USD 1.90 billion in 2024 and is projected to grow to USD 2.02 billion in 2025, with a CAGR of 6.63%, reaching USD 3.17 billion by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.90 billion
Estimated Year [2025] USD 2.02 billion
Forecast Year [2032] USD 3.17 billion
CAGR (%) 6.63%

Setting the stage for an integrated and patient-centered view of breast biopsy care that connects clinical outcomes, device innovation, and institutional strategy

The diagnostic pathway for breast disease hinges on timely, accurate, and minimally invasive tissue sampling. Advances in imaging and device engineering have diversified the array of biopsy options available to clinicians, while patient expectations for safety and comfort have shifted procedural priorities. Consequently, institutional decision-makers, manufacturers, and clinical teams must reconcile rising demand for precision with operational constraints in multiple care settings.

This introduction establishes the context for deeper analysis by outlining the evolving intersections of technology, clinical practice, and health system delivery. It highlights the growing emphasis on procedure personalization, cross-disciplinary collaboration, and data-driven quality assurance. Moreover, it underscores how regulatory emphasis on device safety and comparative effectiveness is reshaping product development cycles and adoption pathways. By framing the topic in terms of clinical outcomes, throughput, and patient experience, the subsequent sections will explore the strategic implications for stakeholders across the value chain.

How converging imaging advances, device modularity, and patient-centered delivery models are reshaping clinical workflows and procurement priorities in breast biopsy care

The landscape for breast biopsy is undergoing transformative shifts driven by technological miniaturization, imaging convergence, and a renewed focus on patient-centric workflows. Imaging modalities such as high-resolution ultrasound and advanced MRI sequences have become more accessible and interoperable, enabling clinicians to target lesions with greater accuracy and reduced procedure time. At the same time, device manufacturers have converged on modular designs that prioritize ergonomics, real-time feedback, and compatibility with multiple imaging platforms.

These shifts are also reflected in care delivery models: outpatient and ambulatory environments increasingly perform diagnostically complex procedures previously restricted to inpatient settings, driven by efficiency and patient convenience. Meanwhile, clinical pathways emphasize shared decision-making, which requires clearer communication of biopsy risks, benefits, and expected diagnostic value. Taken together, these trends are rewriting procurement priorities, operator training requirements, and vendor collaborations, creating new opportunities and competitive pressures for stakeholders prepared to adapt.

Assessing the downstream operational and supply chain consequences of tariff adjustments during 2025 and how stakeholders realigned sourcing and procurement strategies

Policy instruments that alter the economic calculus of device procurement and clinical reimbursement can produce ripple effects throughout the supply chain and care continuum. Tariff adjustments implemented in 2025 introduced discrete cost pressures that influenced sourcing decisions, pricing strategies, and the geographic orientation of inventory management. Procurement teams responded by reassessing supplier diversity, optimizing logistics, and seeking contractual protections that mitigate exposure to cross-border tariff volatility.

In parallel, manufacturers evaluated their manufacturing footprints and aftermarket support models to preserve margin and ensure continuity of supply. Regulatory compliance and quality assurance remained top priorities during these adjustments, prompting incremental investments in domestic assembly and validated distribution channels. Clinicians and health system leaders adapted by reexamining case mix and scheduling patterns to absorb incremental unit costs without compromising access. Ultimately, the tariff environment underscored the importance of flexible sourcing strategies and proactive commercial planning to sustain service levels amid shifting trade conditions.

Detailed segmentation analysis across device technologies, procedural modalities, and end-user settings to inform targeted commercialization and clinical adoption strategies

Segmentation insights reveal nuanced demand drivers that vary across technology, procedure type, and end-user settings and therefore require differentiated commercial and clinical strategies. Within technology, Core Needle Biopsy Devices account for a substantial portion of procedural choices and are available in automated and semi-automated configurations that balance throughput with operator control. Fine Needle Aspiration Needles include echo-enhanced variants for improved sonographic visualization alongside standard needles that remain relevant for cytology-driven workflows. Vacuum-Assisted Systems present a bifurcated product set with handheld devices optimized for point-of-care convenience and table-configured platforms designed for complex lesion access and high-volume environments.

Procedure-type segmentation further informs device selection and training priorities. MRI-guided approaches are differentiated by closed-bore and open-bore systems, each aligning with specific lesion visibility and patient tolerance considerations. Palpation-guided procedures persist as pragmatic options through freehand palpation and grid-guided techniques where imaging access is limited. Stereotactic biopsies comprise prone and upright configurations, which influence patient positioning, imaging geometry, and procedure time. Ultrasound-guided interventions vary between 2D and emerging 3D imaging capabilities, which affect targeting precision and operator learning curves. Finally, end-user segmentation clarifies where demand concentrates and how procurement and operational criteria diverge: Ambulatory Surgery Centers, including diagnostic centers and outpatient surgery centers, prioritize throughput and per-procedure cost-efficiency; Hospitals, spanning private and public institutions, emphasize comprehensive service portfolios and robust inventory support; Specialty Clinics, such as oncology and radiology clinics, focus on clinical specialization, integrated diagnostics, and patient navigation. Together, these segmentation lenses illuminate where innovation, service models, and commercial engagement will have the highest strategic impact.

Regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, distribution, and clinical support priorities

Regional dynamics shape both clinical practice patterns and commercial imperatives, and a geographically nuanced view helps stakeholders prioritize market entry, distribution, and support investments. In the Americas, health systems emphasize value-based care, procedural efficiency, and outpatient expansion, creating demand for user-friendly devices and integrated workflow solutions. Reimbursement mechanisms and hospital procurement processes in this region tend to favor demonstrable clinical benefit and robust post-market support.

In Europe, Middle East & Africa, diverse regulatory regimes and heterogeneous infrastructure create a mosaic of opportunity and constraint. Some markets in this region adopt advanced imaging and device platforms rapidly, while others prioritize cost-effective, scalable solutions that can be deployed across variable care settings. Local manufacturing, regulatory harmonization, and training partnerships often become differentiators. Asia-Pacific presents a broad spectrum of adoption trajectories where rapid hospital modernization and rising screening programs drive demand for precision biopsy solutions; meanwhile, market entrants must navigate local regulatory pathways, distribution networks, and clinician training needs to realize sustainable uptake. Understanding these regional contours allows manufacturers and health system planners to tailor product portfolios, commercial models, and support services for maximal clinical and operational relevance.

Competitive landscape and company-level strategic signals highlighting differentiation through integrated solutions, clinical partnerships, and service excellence

Competitive dynamics in the breast biopsy ecosystem are characterized by technology differentiation, service-led value propositions, and strategic collaboration. Leading device developers increasingly couple hardware offerings with digital tools that enhance procedural planning, documentation, and post-procedure tracking. As a result, companies that can demonstrate end-to-end solutions-combining device reliability, imaging interoperability, and data integration-are better positioned to secure long-term institutional relationships.

Partnerships between device manufacturers, imaging vendors, and clinical centers accelerate innovation cycles and support the development of clinically validated workflows. Moreover, supply chain resilience, regulatory responsiveness, and service excellence serve as critical decision criteria for hospital systems and specialty clinics. New entrants tend to focus on niche innovations-such as ergonomic designs or disposable components-to gain initial traction, while established players leverage scale, global distribution networks, and clinical evidence to defend market positions. Ultimately, the competitive landscape rewards organizations that invest in clinician training, post-market surveillance, and meaningful outcome-based evidence.

Actionable strategic playbook for manufacturers and health systems to align innovation, enablement, and supply chain resilience to accelerate adoption and value realization

Industry leaders should pursue a balanced strategy that aligns product innovation with operational support and clinician enablement to accelerate adoption and sustain value. First, prioritize device designs that enhance procedural ergonomics and imaging compatibility while reducing setup complexity; this approach shortens learning curves and improves throughput. Second, invest in clinician education programs and simulation-based training that reinforce technique consistency and support quality metrics. Third, expand service offerings beyond hardware to include procedural workflow consulting, remote troubleshooting, and outcome-tracking tools that create stickier customer relationships.

Furthermore, diversify supply chain options to mitigate tariff and logistics-related disruptions by combining localized assembly with strategic inventory hubs. Forge partnerships with imaging vendors and specialty clinics to validate integrated workflows and produce real-world evidence that resonates with payers and procurement committees. Lastly, adopt flexible commercial models-ranging from per-procedure consumable pricing to bundled solution contracts-to accommodate diverse customer budgets and accelerate adoption across ambulatory, hospital, and specialty settings. These combined actions will help organizations translate innovation into measurable clinical and commercial gains.

Robust, multi-source research methodology combining literature synthesis, clinician interviews, and data triangulation to validate strategic insights and mitigate analytical limitations

This research synthesizes evidence from a structured and transparent methodology designed to ensure analytical rigor and practical relevance. The approach began with a comprehensive review of peer-reviewed clinical literature, regulatory filings, and technical device documentation to establish a baseline understanding of safety profiles, procedural indications, and device characteristics. Next, qualitative primary research included interviews with practicing interventional radiologists, breast surgeons, procurement leaders, and device engineers to surface real-world adoption drivers, barriers, and unmet needs.

Data triangulation ensured consistency between primary insights and secondary sources, and validation workshops with clinical advisors refined interpretations and prioritized strategic implications. Analytical methods included comparative device feature mapping, procedural pathway analysis, and supply chain risk assessment. The research also documents methodological limitations, such as variability in practice patterns across regions and the evolving nature of imaging technology, and describes mitigation strategies like purposive sampling of experts and sensitivity checks. Ethical considerations governed confidentiality, informed consent for all interviews, and anonymization of practitioner-level data to preserve professional privacy.

Synthesis of strategic imperatives showing how clinical evidence, commercialization agility, and operational resilience will determine long-term success in breast biopsy care

The synthesis of clinical trends, technological progress, and operational realities points to a near-term agenda where precision, patient experience, and supply chain resilience intersect as primary determinants of success. Devices that offer clear improvements in targeting accuracy, ergonomics, and interoperability with imaging systems will find receptive clinical audiences when supported by robust training and service commitments. Meanwhile, health systems will continue to emphasize procedural throughput and cost control, creating demand for modular solutions that can be deployed across ambulatory and hospital settings.

In summary, stakeholders that integrate clinical evidence generation, flexible commercial models, and resilient supply strategies will be best positioned to capture value and improve patient outcomes. As the landscape evolves, continuous engagement with clinicians, proactive investment in post-market evidence, and adaptive commercial planning will remain essential to sustaining momentum and translating innovation into routine practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Biopsy Market, by Product Type

  • 8.1. Biopsy Needles
  • 8.2. Guidance Systems
  • 8.3. Biopsy Guns
  • 8.4. Consumables & Accessories

9. Breast Biopsy Market, by Procedure Type

  • 9.1. Core Needle Biopsy
  • 9.2. Vacuum-Assisted Biopsy
  • 9.3. Fine Needle Aspiration Biopsy
  • 9.4. Surgical/Open Biopsy
    • 9.4.1. Excisional Biopsy
    • 9.4.2. Incisional Biopsy

10. Breast Biopsy Market, by Guidance Modality

  • 10.1. Ultrasound-Guided Biopsy
  • 10.2. Stereotactic X-Ray-Guided Biopsy
  • 10.3. MRI-Guided Biopsy

11. Breast Biopsy Market, by Biopsy Site

  • 11.1. Breast Parenchyma
  • 11.2. Axillary & Regional Lymph Nodes
  • 11.3. Nipple & Ductal Structures

12. Breast Biopsy Market, by End User

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Breast Biopsy Market, by Clinical Indication

  • 13.1. Early Cancer Screening
  • 13.2. Therapy Selection
  • 13.3. Recurrence & Treatment Monitoring

14. Breast Biopsy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Breast Biopsy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Breast Biopsy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Breast Biopsy Market

18. China Breast Biopsy Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. Argon Medical Devices, Inc.
  • 19.6. Becton Dickinson and Company
  • 19.7. Cook Group Incorporated
  • 19.8. Danaher Corporation
  • 19.9. Exact Sciences Corporation
  • 19.10. FUJIFILM Corporation
  • 19.11. GE HealthCare
  • 19.12. Hologic, Inc.
  • 19.13. Medtronic PLC
  • 19.14. Merit Medical Systems, Inc.
  • 19.15. Siemens Healthineers AG
  • 19.16. Sysmex Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST BIOPSY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL BREAST BIOPSY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST BIOPSY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST BIOPSY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BREAST BIOPSY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY GUNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY GUNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY GUNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREAST BIOPSY MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST BIOPSY MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREAST BIOPSY MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST BIOPSY MARKET SIZE, BY EXCISIONAL BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST BIOPSY MARKET SIZE, BY EXCISIONAL BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST BIOPSY MARKET SIZE, BY EXCISIONAL BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST BIOPSY MARKET SIZE, BY INCISIONAL BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST BIOPSY MARKET SIZE, BY INCISIONAL BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST BIOPSY MARKET SIZE, BY INCISIONAL BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST BIOPSY MARKET SIZE, BY ULTRASOUND-GUIDED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST BIOPSY MARKET SIZE, BY ULTRASOUND-GUIDED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST BIOPSY MARKET SIZE, BY ULTRASOUND-GUIDED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST BIOPSY MARKET SIZE, BY STEREOTACTIC X-RAY-GUIDED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST BIOPSY MARKET SIZE, BY STEREOTACTIC X-RAY-GUIDED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST BIOPSY MARKET SIZE, BY STEREOTACTIC X-RAY-GUIDED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST BIOPSY MARKET SIZE, BY MRI-GUIDED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST BIOPSY MARKET SIZE, BY MRI-GUIDED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST BIOPSY MARKET SIZE, BY MRI-GUIDED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST BIOPSY MARKET SIZE, BY BREAST PARENCHYMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST BIOPSY MARKET SIZE, BY BREAST PARENCHYMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST BIOPSY MARKET SIZE, BY BREAST PARENCHYMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST BIOPSY MARKET SIZE, BY AXILLARY & REGIONAL LYMPH NODES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST BIOPSY MARKET SIZE, BY AXILLARY & REGIONAL LYMPH NODES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST BIOPSY MARKET SIZE, BY AXILLARY & REGIONAL LYMPH NODES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST BIOPSY MARKET SIZE, BY NIPPLE & DUCTAL STRUCTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST BIOPSY MARKET SIZE, BY NIPPLE & DUCTAL STRUCTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST BIOPSY MARKET SIZE, BY NIPPLE & DUCTAL STRUCTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BREAST BIOPSY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST BIOPSY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BREAST BIOPSY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BREAST BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BREAST BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BREAST BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BREAST BIOPSY MARKET SIZE, BY RECURRENCE & TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST BIOPSY MARKET SIZE, BY RECURRENCE & TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BREAST BIOPSY MARKET SIZE, BY RECURRENCE & TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BREAST BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NATO BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 186. NATO BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. NATO BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)